GLP-1 Drugs Like Ozempic May Raise Rare Eye Risk

A newly published peer-reviewed paper in the journal Neurology is raising questions about whether GLP-1 receptor agonist medications — including Ozempic and similar drugs — may be associated with an elevated risk of a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION. The finding adds a new layer to the ongoing conversation about the benefit-risk profile of this widely used class of medications.

What Is NAION?

NAION is a condition in which blood flow to the optic nerve is suddenly reduced, potentially causing permanent vision loss — typically in one eye at a time. It is considered rare in the general population and is sometimes described as a "stroke of the eye." Existing risk factors include sleep apnea, small optic nerve anatomy, high blood pressure, and diabetes. Because type 2 diabetes and obesity — the primary conditions GLP-1 drugs are prescribed to treat — overlap with known NAION risk factors, understanding the independent contribution of these medications is scientifically complex.

What the Neurology Paper Examines

The paper, titled GLP-1 Receptor Agonists and NAION: A Risk Worth Taking? and published in Neurology, specifically addresses the question of whether GLP-1 receptor agonists carry a meaningful NAION risk. The framing of the title — "a risk worth taking" — signals that the authors are weighing potential harms against the well-documented cardiovascular, metabolic, and weight-related benefits of this drug class. The article does not appear to argue against using these medications outright, but rather calls for more careful consideration of the risk in clinical practice.

What This Means for Patients on GLP-1 Medications

For the millions of people currently taking semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or other GLP-1 receptor agonists, this publication does not signal an immediate need to stop medication. A single peer-reviewed paper — even in a prestigious journal — is one data point in a much larger body of evidence. However, patients should be aware of the following:

• Sudden or unexplained changes in vision, particularly in one eye, should be treated as a medical emergency regardless of what medications you take.
• Patients with a history of optic nerve problems, NAION in one eye, or other structural eye concerns may want to proactively discuss this research with their prescriber or ophthalmologist.
• The substantial benefits of GLP-1 drugs — including reduced cardiovascular events and meaningful weight loss — remain well-established and should be part of any risk-benefit discussion.

What to Watch For Next

This publication in Neurology is likely to prompt additional scrutiny from researchers, ophthalmologists, and potentially regulatory agencies. Patients and clinicians should watch for follow-up studies with larger populations, any updates to prescribing information or FDA safety communications, and guidance from ophthalmology societies on monitoring recommendations for people on GLP-1 therapy. No regulatory body has issued a warning or label change based on this research at this time.

Frequently Asked Questions

As always, any decisions about starting, continuing, or stopping a GLP-1 medication should be made in close consultation with your prescriber, who can evaluate your complete medical history, current risk factors, and personal treatment goals in light of evolving research like this.